Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1992 Jul;90(1):67–76. doi: 10.1172/JCI115857

Fibrinogen Lima: a homozygous dysfibrinogen with an A alpha-arginine-141 to serine substitution associated with extra N-glycosylation at A alpha-asparagine-139. Impaired fibrin gel formation but normal fibrin-facilitated plasminogen activation catalyzed by tissue-type plasminogen activator.

H Maekawa 1, K Yamazumi 1, S Muramatsu 1, M Kaneko 1, H Hirata 1, N Takahashi 1, C L Arocha-Piñango 1, S Rodriguez 1, H Nagy 1, J L Perez-Requejo 1, et al.
PMCID: PMC443064  PMID: 1634621

Abstract

An A alpha-arginine-141 to serine substitution has been identified in a homozygous dysfibrinogen, fibrinogen Lima, associated with impaired fibrin polymerization. The point mutation created an asparagine-X-serine-type glycosylation sequence, and indeed, extra, mainly disialylated biantennary oligosaccharides have been isolated from A alpha asparagine-139 of the patient's fibrinogen. This type of glycosylation sequence is unique for human fibrinogen, because the sequences shown for normal and abnormal fibrinogens are all asparagine-X-threonine types. The terminal sialic acids of the extra oligosaccharides seem to have largely contributed to the impaired fibrin gel formation, as evidenced by its correction to a near normal level by desialylation. Nevertheless, the polymerizing fibrin facilitated tissue-type plasminogen activator-catalyzed plasmin formation in a normal fashion, indicating that the initial two-stranded fibrin protofibrils had been constructed normally. Thus the impaired fibrin gel formation could be attributed to the delay in their subsequent lateral association, most probably because of the repulsive forces generated by the negative electric charge of the extra sialic acids. The substitution of a basic residue arginine to a noncharged residue serine may also have contributed to the impaired function in a similar manner or by steric hindrance in association with bulky extra oligosaccharide chains.

Full text

PDF
67

Images in this article

70Image
on p.70
70Image
on p.70
70Image
on p.70
73Image
on p.73

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arocha-Piñango C. L., Rodriguez S., Nagy H., Perez Requejo J. L. Fibrinogen Lima. A new dysfibrinogenaemia with a high-molecular-weight alpha-chain and effective polymerization. Blood Coagul Fibrinolysis. 1990 Oct;1(4-5):561–565. doi: 10.1097/00001721-199010000-00040. [DOI] [PubMed] [Google Scholar]
  2. Barlow G. H., Summaria L., Robbins K. C. Molecular weight studies on human plasminogen and plasmin at the microgram level. J Biol Chem. 1969 Mar 10;244(5):1138–1141. [PubMed] [Google Scholar]
  3. Blombäck B., Hessel B., Hogg D., Therkildsen L. A two-step fibrinogen--fibrin transition in blood coagulation. Nature. 1978 Oct 12;275(5680):501–505. doi: 10.1038/275501a0. [DOI] [PubMed] [Google Scholar]
  4. CLAUSS A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957 Apr;17(4):237–246. doi: 10.1159/000205234. [DOI] [PubMed] [Google Scholar]
  5. Deutsch D. G., Mertz E. T. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970 Dec 4;170(3962):1095–1096. doi: 10.1126/science.170.3962.1095. [DOI] [PubMed] [Google Scholar]
  6. Doolittle R. F. Structural aspects of the fibrinogen to fibrin conversion. Adv Protein Chem. 1973;27:1–109. doi: 10.1016/s0065-3233(08)60446-5. [DOI] [PubMed] [Google Scholar]
  7. Engesser L., Koopman J., de Munk G., Haverkate F., Nováková I., Verheijen J. H., Briët E., Brommer E. J. Fibrinogen Nijmegen: congenital dysfibrinogenemia associated with impaired t-PA mediated plasminogen activation and decreased binding of t-PA. Thromb Haemost. 1988 Aug 30;60(1):113–120. [PubMed] [Google Scholar]
  8. Fowler W. E., Hantgan R. R., Hermans J., Erickson H. P. Structure of the fibrin protofibril. Proc Natl Acad Sci U S A. 1981 Aug;78(8):4872–4876. doi: 10.1073/pnas.78.8.4872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Galanakis D. K., Mosesson M. W. Evaluation of the role of in vivo proteolysis (fibrinogenolysis) in prolonging the thrombin time of human umbilical cord fibrinogen. Blood. 1976 Jul;48(1):109–118. [PubMed] [Google Scholar]
  10. Gollwitzer R., Timpl R., Becker U., Furthmayr H. Chemical and immunological properties of reduced and alkylated polypeptide chains of bovine fibrinogen. Eur J Biochem. 1972 Aug 4;28(4):497–506. doi: 10.1111/j.1432-1033.1972.tb01937.x. [DOI] [PubMed] [Google Scholar]
  11. Hase S., Ibuki T., Ikenaka T. Reexamination of the pyridylamination used for fluorescence labeling of oligosaccharides and its application to glycoproteins. J Biochem. 1984 Jan;95(1):197–203. doi: 10.1093/oxfordjournals.jbchem.a134585. [DOI] [PubMed] [Google Scholar]
  12. Haverkate F., Koopman J., Kluft C., D'Angelo A., Cattaneo M., Mannucci P. M. Fibrinogen Milano II: a congenital dysfibrinogenaemia associated with juvenile arterial and venous thrombosis. Thromb Haemost. 1986 Feb 28;55(1):131–135. [PubMed] [Google Scholar]
  13. Hewick R. M., Hunkapiller M. W., Hood L. E., Dreyer W. J. A gas-liquid solid phase peptide and protein sequenator. J Biol Chem. 1981 Aug 10;256(15):7990–7997. [PubMed] [Google Scholar]
  14. INGRAM G. I., MATCHETT M. O. A rapid "side-room" method for the determination of plasma fibrinogen concentration as fibrin. J Clin Pathol. 1960 Nov;13:469–474. doi: 10.1136/jcp.13.6.469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kehl M., Lottspeich F., Henschen A. Analysis of human fibrinopeptides by high-performance liquid chromatography. Hoppe Seylers Z Physiol Chem. 1981 Dec;362(12):1661–1664. [PubMed] [Google Scholar]
  16. Kudryk B. J., Collen D., Woods K. R., Blombäck B. Evidence for localization of polymerization sites in fibrinogen. J Biol Chem. 1974 May 25;249(10):3322–3325. [PubMed] [Google Scholar]
  17. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  18. Langer B. G., Weisel J. W., Dinauer P. A., Nagaswami C., Bell W. R. Deglycosylation of fibrinogen accelerates polymerization and increases lateral aggregation of fibrin fibers. J Biol Chem. 1988 Oct 15;263(29):15056–15063. [PubMed] [Google Scholar]
  19. Laudano A. P., Doolittle R. F. Synthetic peptide derivatives that bind to fibrinogen and prevent the polymerization of fibrin monomers. Proc Natl Acad Sci U S A. 1978 Jul;75(7):3085–3089. doi: 10.1073/pnas.75.7.3085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lorand L., Credo R. B., Janus T. J. Factor XIII (fibrin-stabilizing factor). Methods Enzymol. 1981;80(Pt 100):333–341. doi: 10.1016/s0076-6879(81)80029-8. [DOI] [PubMed] [Google Scholar]
  21. Lundblad R. L. A rapid method for the purification of bovine thrombin and the inhibition of the purified enzyme wtih phenylmethylsulfonyl fluoride. Biochemistry. 1971 Jun 22;10(13):2501–2506. doi: 10.1021/bi00789a012. [DOI] [PubMed] [Google Scholar]
  22. Maekawa H., Yamazumi K., Muramatsu S., Kaneko M., Hirata H., Takahashi N., de Bosch N. B., Carvajal Z., Ojeda A., Arocha-Piñango C. L. An A alpha Ser-434 to N-glycosylated Asn substitution in a dysfibrinogen, fibrinogen Caracas II, characterized by impaired fibrin gel formation. J Biol Chem. 1991 Jun 25;266(18):11575–11581. [PubMed] [Google Scholar]
  23. Marder V. J., Shulman N. R., Carroll W. R. High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. J Biol Chem. 1969 Apr 25;244(8):2111–2119. [PubMed] [Google Scholar]
  24. Martinez J., MacDonald K. A., Palascak J. E. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood. 1983 Jun;61(6):1196–1202. [PubMed] [Google Scholar]
  25. Martinez J., Palascak J. E., Kwasniak D. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. J Clin Invest. 1978 Feb;61(2):535–538. doi: 10.1172/JCI108964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Martinez J., Palascak J., Peters C. Functional and metabolic properties of human asialofibrinogen. J Lab Clin Med. 1977 Feb;89(2):367–377. [PubMed] [Google Scholar]
  27. Matsuda M., Baba M., Morimoto K., Nakamikawa C. "Fibrinogen Tokyo II". An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules. J Clin Invest. 1983 Sep;72(3):1034–1041. doi: 10.1172/JCI111027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Nishibe H., Takahashi N. The release of carbohydrate moieties from human fibrinogen by almond glycopeptidase without alteration in fibrinogen clottability. Biochim Biophys Acta. 1981 Oct 13;661(2):274–279. doi: 10.1016/0005-2744(81)90015-2. [DOI] [PubMed] [Google Scholar]
  29. Olexa S. A., Budzynski A. Z. Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci U S A. 1980 Mar;77(3):1374–1378. doi: 10.1073/pnas.77.3.1374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Park K., Gerndt S. J., Cooper S. L. The effect of fibrinogen sialic acid residues on ex vivo platelet deposition on biomaterials. Thromb Res. 1986 Aug 1;43(3):293–302. doi: 10.1016/0049-3848(86)90149-0. [DOI] [PubMed] [Google Scholar]
  31. Schielen W. J., Voskuilen M., Adams P. J., Tesser G. I., Nieuwenhuizen W. Structural requirements of fibrinogen A alpha-(148-160) for the enhancement of the rate of plasminogen activation by tPA. Blood Coagul Fibrinolysis. 1990 Oct;1(4-5):521–524. doi: 10.1097/00001721-199010000-00030. [DOI] [PubMed] [Google Scholar]
  32. Schwartz M. L., Pizzo S. V., Hill R. L., McKee P. A. Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem. 1973 Feb 25;248(4):1395–1407. [PubMed] [Google Scholar]
  33. Suenson E., Bjerrum P., Holm A., Lind B., Meldal M., Selmer J., Petersen L. C. The role of fragment X polymers in the fibrin enhancement of tissue plasminogen activator-catalyzed plasmin formation. J Biol Chem. 1990 Dec 25;265(36):22228–22237. [PubMed] [Google Scholar]
  34. Terukina S., Matsuda M., Hirata H., Takeda Y., Miyata T., Takao T., Shimonishi Y. Substitution of gamma Arg-275 by Cys in an abnormal fibrinogen, "fibrinogen Osaka II". Evidence for a unique solitary cystine structure at the mutation site. J Biol Chem. 1988 Sep 25;263(27):13579–13587. [PubMed] [Google Scholar]
  35. Terukina S., Yamazumi K., Okamoto K., Yamashita H., Ito Y., Matsuda M. Fibrinogen Kyoto III: a congenital dysfibrinogen with a gamma aspartic acid-330 to tyrosine substitution manifesting impaired fibrin monomer polymerization. Blood. 1989 Dec;74(8):2681–2687. [PubMed] [Google Scholar]
  36. Tesch R., Trolp R., Witt I. Electron microscopic studies on the foetal fibrin clot. Thromb Res. 1979;16(1-2):239–243. doi: 10.1016/0049-3848(79)90284-6. [DOI] [PubMed] [Google Scholar]
  37. Tomiya N., Awaya J., Kurono M., Endo S., Arata Y., Takahashi N. Analyses of N-linked oligosaccharides using a two-dimensional mapping technique. Anal Biochem. 1988 May 15;171(1):73–90. doi: 10.1016/0003-2697(88)90126-1. [DOI] [PubMed] [Google Scholar]
  38. Tomiya N., Kurono M., Ishihara H., Tejima S., Endo S., Arata Y., Takahashi N. Structural analysis of N-linked oligosaccharides by a combination of glycopeptidase, exoglycosidases, and high-performance liquid chromatography. Anal Biochem. 1987 Jun;163(2):489–499. doi: 10.1016/0003-2697(87)90253-3. [DOI] [PubMed] [Google Scholar]
  39. Townsend R. R., Hardy M. R., Hindsgaul O., Lee Y. C. High-performance anion-exchange chromatography of oligosaccharides using pellicular resins and pulsed amperometric detection. Anal Biochem. 1988 Nov 1;174(2):459–470. doi: 10.1016/0003-2697(88)90044-9. [DOI] [PubMed] [Google Scholar]
  40. Townsend R. R., Hilliker E., Li Y. T., Laine R. A., Bell W. R., Lee Y. C. Carbohydrate structure of human fibrinogen. Use of 300-MHz 1H-NMR to characterize glycosidase-treated glycopeptides. J Biol Chem. 1982 Aug 25;257(16):9704–9710. [PubMed] [Google Scholar]
  41. Voskuilen M., Vermond A., Veeneman G. H., van Boom J. H., Klasen E. A., Zegers N. D., Nieuwenhuizen W. Fibrinogen lysine residue A alpha 157 plays a crucial role in the fibrin-induced acceleration of plasminogen activation, catalyzed by tissue-type plasminogen activator. J Biol Chem. 1987 May 5;262(13):5944–5946. [PubMed] [Google Scholar]
  42. Weber K., Osborn M. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem. 1969 Aug 25;244(16):4406–4412. [PubMed] [Google Scholar]
  43. Yamazumi K., Shimura K., Terukina S., Takahashi N., Matsuda M. A gamma methionine-310 to threonine substitution and consequent N-glycosylation at gamma asparagine-308 identified in a congenital dysfibrinogenemia associated with posttraumatic bleeding, fibrinogen Asahi. J Clin Invest. 1989 May;83(5):1590–1597. doi: 10.1172/JCI114056. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES